

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 03/086385 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/341**,  
31/40, 31/42, 31/433, 31/415, 31/4192, 31/4439, 31/404,  
31/4709, 31/4427, 31/4196, 31/4162, 31/497, 31/427,  
C07D 307/32, 207/26, 207/12, 413/06, 417/06, 403/12,  
403/06, 407/06, 409/06, 401/06, 237/22

Box 13398, Research Triangle Park, NC 27709 (US).  
SAMANO, Vicente [US/US]; c/o GlaxoSmithKline, Five  
Moore Drive, PO Box 13398, Research Triangle Park, NC  
27709 (US).

(21) International Application Number: PCT/US03/09893

(74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Corporate  
Intellectual Property Dept, Five Moore Drive, PO Box  
13398, Research Triangle Park, NC 27709 (US).

(22) International Filing Date: 1 April 2003 (01.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/371,524 10 April 2002 (10.04.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):  
SMITHKLINE BEECHAM CORPORATION  
[US/US]; One Franklin Plaza, Philadelphia, PA 19101  
(US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BARRETT,  
David, Gene [US/DE]; Elsa-Brandstrom-Stieg 2, 22846  
Norderstedt (DE). CATALANO, John, G. [US/US]; c/o  
GlaxoSmithKline, Five Moore Drive, PO Box 13398,  
Research Triangle Park, NC 27709 (US). DEATON,  
David, Norman [US/US]; c/o GlaxoSmithKline, Five  
Moore Drive, PO Box 13398, Research Triangle Park,  
NC 27709 (US). MILLER, Aaron, Bayne [US/US]; c/o  
GlaxoSmithKline, Five Moore Drive, PO Box 13398,  
Research Triangle Park, NC 27709 (US). RAY, John, A  
[US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE  
TREATMENT OF BONE LOSS

(57) Abstract: Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, Z and R are defined as in  
claim 1, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making  
such heterocycle substituted ketoamide derivatives as well as methods of using the same in the manufacture of medicaments for  
the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can  
ultimately lead to fracture.

WO 03/086385 A1